Iranian drug maker starts clinical studies on Omicron jab

An Iranian pharmaceutical company says it has has started clinical studies on a vaccine exclusively for the Omicron variant of Covid.

The vaccine has been dubbed Barakat-Plus.

Hassan Jalili the CEO of Iran’s Shafa PharMed factory said on Monday morning, Iran’s Health Ministry, after reviewing the scientific documentation, issued a code of conduct for the clinical study of the Barakat Plus vaccine.

In this study, all persons over 18 years of age who have previously received two doses of Cov-Iran Barakat or Sinopharm vaccine can be candidates for the Omicron jab.

“At this stage, the vaccine will be administered to 210 volunteers, and the preliminary results will be presented to the Food and Drug Organization two weeks after receiving the booster shot,” he said.

Regarding the latest statistics on the production of the first Iranian Covid vaccine, the CEO of Shafa PharMed factory said so far, about 60 million doses of CovIran Barakat vaccine have been produced in by the company.

IFP Editorial Staff

The IFP Editorial Staff is composed of dozens of skilled journalists, news-writers, and analysts whose works are edited and published by experienced editors specialized in Iran News. The editor of each IFP Service is responsible for the report published by the Iran Front Page (IFP) news website, and can be contacted through the ways mentioned in the "IFP Editorial Staff" section.